PolyPid Ltd. — FY2021 Form 20-F
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone 2021 fourth-quarter report; the filing text does not provide separate Q4 financial results. Amounts below are U.S. dollars unless noted.
Business context and reporting period
PolyPid is an Israeli Phase 3 clinical-stage biopharmaceutical company developing locally administered, prolonged-release therapies using its PLEX technology. Its lead candidate, D-PLEX 100, combines PLEX with doxycycline and is being developed to prevent surgical site infections (SSIs). The company had no approved products and had generated no product-sales revenue. Its earlier-stage OncoPLEX program targets tumors; in November 2021, the FDA held a successful pre-IND meeting supporting a planned Phase 1/2 trial for glioblastoma.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development, net | $30.6 million | $17.0 million |
| Marketing and business development | $3.0 million | $1.6 million |
| General and administrative | $9.6 million | $7.7 million |
| Operating loss | $43.1 million | $26.3 million |
| Net loss | $42.6 million | $36.9 million |
| Net loss per ordinary share | $2.28 | $4.48 |
| Net cash used in operating activities | $32.4 million | $21.6 million |
Gross margin and operating margin are not meaningful because PolyPid had no product revenue. R&D expense increased by $13.6 million, primarily due to $9.8 million of costs associated with starting the SHIELD I and SHIELD II Phase 3 trials, higher manufacturing-facility costs, additional R&D and personnel expenses, and share-based compensation; higher IIA grant income partly offset the increase. G&A and commercial-development spending also rose. The 2020 loss included a $11.4 million non-cash warrant remeasurement expense; the 2021 financial result was net income of $0.5 million, largely from deposit interest and foreign-exchange effects.
At December 31, 2021, cash and cash equivalents were $9.8 million, short-term deposits $22.4 million, and restricted cash $0.4 million. Cash, cash equivalents and short-term deposits totaled $32.2 million, down from $44.5 million at year-end 2020. Total assets were $44.2 million; current liabilities were $8.1 million, long-term liabilities $0.2 million, and shareholders’ equity $36.0 million. The filing reports no material ongoing financing commitments such as credit lines; lease commitments totaled $4.7 million. No conventional borrowings are shown on the balance sheet.
Financing cash flow was $1.0 million in 2021, mainly from warrant and option exercises, versus $62.8 million in 2020, when the IPO generated net proceeds of $62.8 million. Investing cash flow was $36.9 million in 2021, principally reflecting releases of deposits. The company spent $4.0 million on capital expenditures in 2021.
Material changes and developments
- Operating loss rose $16.9 million year over year as the company expanded late-stage clinical and related activities.
- Operating cash use increased $10.8 million year over year. Accumulated deficit reached $174.9 million.
- The FDA agreed in May 2021 that one adequate pivotal Phase 3 study could support a D-PLEX 100 NDA for colorectal-surgery SSIs. In January 2022, a blinded reassessment supported continuing SHIELD I; the FDA then agreed to an unblinded interim analysis after 750 patients complete 30-day follow-up.
- SHIELD II enrollment was reported at over 200 patients as of February 28, 2022. Enrollment in the Phase 3 cardiac-surgery trial remained paused, with the company evaluating next steps.
- The company had 18,756,570 ordinary shares outstanding at December 31, 2021. A $45 million at-the-market offering facility was established in July 2021; no shares had been sold under it as of February 28, 2022.
Outlook, risks and unusual items
Management expected existing cash and short-term deposits to fund operating expenses and capital expenditures through the end of 2022 and anticipated completing and reporting SHIELD I results with those funds. It expected additional capital would be needed to complete SHIELD II, resume the cardiac trial, advance OncoPLEX, and commercialize D-PLEX 100 if approved. The auditor’s report and the financial-statement note identify substantial doubt about the company’s ability to continue as a going concern; the statements contain no adjustments for the outcome of that uncertainty. Management cited potential equity or debt financing, grants, partnerships and cost controls as possible responses.
Management expected losses and expenses to continue increasing, with no product revenue anticipated for at least several years. Key uncertainties include clinical-trial enrollment and outcomes, the SHIELD I interim analysis and any resulting increase in sample size, regulatory acceptance of trial data and the proposed 505(b)(2) pathway, manufacturing scale-up and validation, access to additional funding, and eventual market access and reimbursement. COVID-19 could disrupt trials or supply and may have lowered hospital SSI rates, potentially making trial efficacy harder to demonstrate. The company also cited competition, reliance on third-party suppliers and CROs, foreign-exchange exposure (about 52% of expenses were denominated in NIS), and Israeli Innovation Authority grant restrictions. IIA royalty-bearing grants totaled $4.9 million; royalties of 3% of qualifying product sales, plus interest, may be payable, and transferring supported technology or manufacturing outside Israel can require approval and payments.
As a clinical data point—not FY2021 revenue or proof of Phase 3 success—the company reported that its 201-patient Phase 2 abdominal-surgery trial showed a 59% reduction in the primary endpoint versus standard care (p=0.0086). The company cautioned that Phase 2 results do not predict pivotal-trial outcomes.
Most important facts for investors to verify
- SHIELD I interim-analysis findings, any sample-size reassessment, final enrollment and topline results; separately, SHIELD II progress and the status of the paused cardiac trial.
- Cash burn, actual cash and deposit balances after year-end, and the timing and terms of any additional financing or ATM sales.
- Whether the FDA considers the Phase 3 evidence sufficient for an NDA, the achievable label, and whether the 505(b)(2) pathway remains available.
- Manufacturing-process validation, regulatory readiness and supply capacity, including dependencies on external raw-material suppliers.
- How IIA grant obligations, currency movements and commercialization or reimbursement requirements may affect future cash needs and economics.